InvestSMART

Adherium Limited (ASX:ADR)

ALERT: Price-sensitive ASX Announcement for ADR
Current share price for ADR : $0.002 -0.003 (-60%)+
Announcement
Release
31 Jul 2025 3:56PM
Price at Release
$0.005
Full Release
download
Summary
Adherium Limited's Quarterly Activities/Appendix 4C Cash Flow Report for the quarter ended 31 March 2023 outlines the company's key operational activities, financial performance, and strategic initiatives. The report discusses the progress of commercialisation activities, partnerships, and product development, particularly focusing on the use of its Hailie® technology in respiratory health. The cash flow statement details inflows and outflows, with an emphasis on operating, investing, and financing activities for the period. The company also addresses its cash runway and future funding requirements, highlighting ongoing efforts to optimise costs and pursue revenue growth through commercial and clinical programs. The report reaffirms Adherium’s commitment to advancing digital health solutions in respiratory care and strengthening its position in the market.
Key Points
  • Adherium Limited released its Quarterly Activities/Appendix 4C Cash Flow Report for the quarter ended 31 March 2023.
  • Key operational activities included ongoing commercialisation of Hailie® technology and expansion of digital respiratory health solutions.
  • The company reported on partnerships with pharmaceutical and medical device companies to drive commercial and clinical adoption.
  • Product development efforts continued, with updates on regulatory and technical milestones.
  • Cash flows from operating activities were detailed, highlighting receipts from customers, operational outflows, and R&D expenditure.
  • No significant investing activity was reported for the quarter.
  • Financing activity primarily included receipts from equity placements.
  • Adherium addressed its current cash runway and the need for future funding to support continued growth and operations.
  • The company remains focused on cost optimisation while pursuing new revenue opportunities.
  • Emphasis was placed on advancing digital health solutions and improving patient outcomes in respiratory care.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.